Literature DB >> 14570288

A comparative immunohistochemistry of O6-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas.

Qingguo Yuan1, Kenichi Matsumoto, Yusaku Nakabeppu, Toru Iwaki.   

Abstract

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) removes mutagenic adducts from the O6 position of guanine, thereby protecting the genome against guanine : cytosine to adenine : thymine transition and, meanwhile, conferring tumor resistance to many anti-cancer alkylating agents commonly used in the treatment of malignant gliomas. Studies on the involvement of p53 protein in expression of the MGMT gene have provided conflicting results regarding the relation between p53 protein and MGMT gene expression. To examine the potential immunostaining pattern of MGMT expression and to evaluate the possible relationship between p53 and MGMT regulation, we assessed MGMT and p53 accumulation on 35 cases of diffusely infiltrating astrocytomas. With a few cases showing cytoplasmic staining, MGMT accumulation was mainly nuclear. The percentage of labeled tumor cells was lower in high-grade astrocytomas than in low-grade astrocytomas (P < 0.05). Additionally, p53-immunopositive tumor cells were usually immunonegative to MGMT. Thus, it is suggested that MGMT expression is reduced during malignant transformation of diffusely infiltrating astrocytomas, and that mutant p53 protein might be associated with down regulation of the MGMT expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14570288     DOI: 10.1046/j.1440-1789.2003.00504.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  7 in total

1.  Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.

Authors:  Prabal Deb; N S Mani; S M Sudumbrekar; Nitin Taneja; Seema Patrikar
Journal:  Med J Armed Forces India       Date:  2012-12-01

2.  O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.

Authors:  Sabine Spiegl-Kreinecker; Christine Pirker; Martin Filipits; Daniela Lötsch; Johanna Buchroithner; Josef Pichler; Rene Silye; Serge Weis; Michael Micksche; Johannes Fischer; Walter Berger
Journal:  Neuro Oncol       Date:  2009-10-15       Impact factor: 12.300

3.  Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.

Authors:  Xiang Wang; Jin-xiu Chen; Yan-hui Liu; Chao You; Qing Mao
Journal:  Neurol Sci       Date:  2012-12-08       Impact factor: 3.307

4.  Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma.

Authors:  Brian R Rood; Huizhen Zhang; Philip H Cogen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

5.  Immunohistochemical Assessment of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and Its Relationship with p53 Expression in Endometrial Cancers.

Authors:  Kyung Eun Lee
Journal:  J Cancer Prev       Date:  2013-12

6.  Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma.

Authors:  Qiang Li; Jiang Guo; Weisheng Wang; Dingkun Wang
Journal:  Oncol Lett       Date:  2017-05-05       Impact factor: 2.967

7.  O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.

Authors:  Ken Sasai; Tsuyoshi Akagi; Eiko Aoyanagi; Kouichi Tabu; Sadao Kaneko; Shinya Tanaka
Journal:  Mol Cancer       Date:  2007-06-05       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.